Skip to main
SRDX
SRDX logo

Surmodics (SRDX) Stock Forecast & Price Target

Surmodics (SRDX) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surmodics Inc. is actively enhancing its whole-products solutions strategy, which should facilitate accelerated revenue growth in the future. The establishment of a direct sales force to promote its Pounce thrombectomy and Sublime radial access products is expected to strengthen market presence and drive performance. Although the company's operating expenses have increased due to these investments, the potential for future revenue growth in the Medical Device segment remains a key positive factor for the overall outlook.

Bears say

Surmodics Inc is facing significant challenges within its Medical Device segment, primarily due to declining sales of the SurVeil drug-coated balloon, which has resulted in expectations of further revenue decreases in FY25. The company reports lower license fee revenues and decreased sales to its distributor Abbott, contributing to a negative outlook. Additionally, a drop in coating royalty and license fee catch-up payments exacerbates the financial headwinds facing Surmodics, highlighting a potential downturn in overall growth prospects.

Surmodics (SRDX) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surmodics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surmodics (SRDX) Forecast

Analysts have given Surmodics (SRDX) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Surmodics (SRDX) has a Strong Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surmodics (SRDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.